BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 27062198)

  • 1. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
    Choi SE; Pflum MK
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7084-6. PubMed ID: 23089527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
    Choi SE; Weerasinghe SV; Pflum MK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
    Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
    Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syntheses and Biological Evaluation of Novel Hydroxamic Acid Derivatives Containing Purine Moiety as Histone Deacetylase Inhibitors.
    Xu Z; Yang Y; Mai X; Liu B; Xiong Y; Feng L; Liao Y; Zhang Y; Wang H; Ouyang L; Liu S
    Chem Pharm Bull (Tokyo); 2018; 66(4):439-451. PubMed ID: 29607910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
    Bieliauskas AV; Weerasinghe SV; Pflum MK
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2216-9. PubMed ID: 17307359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
    Tambunan US; Bramantya N; Parikesit AA
    BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
    Shahidul Islam M; Nurul Islam M; Ashraful Hoque M; Nishino N; Kato T; Kim HJ; Ito A; Yoshida M
    Bioorg Chem; 2015 Apr; 59():145-50. PubMed ID: 25797804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
    Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
    Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry.
    Sun Q; Yao Y; Liu C; Li H; Yao H; Xue X; Liu J; Tu Z; Jiang S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3295-9. PubMed ID: 23601706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
    Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
    Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
    Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
    Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
    Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
    Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.